Change in formulation and its potential clinical and pharmacoeconomic value: example of extended release venlafaxine

References

• US Food and Drug Administration. Guidance for Industry: Applications Covered by Section 505(b)(2). http://www.fda.gov/cder/guidance/2853dft.pdf. Accessed December 12, 2008
   Google Scholar
• US Prescribing Information Venlafaxine Extended Release Tablets (venlafaxine hydrochloride). Osmotica Pharmaceutical Corp., Wilmington, NC, May, 2008
   Google Scholar
• US Food and Drug Administration. Drugs@FDA [Query for Effexor]. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed December 12, 2008
   Google Scholar
• US Prescribing Information Effexor XR® (venlafaxine hydrochloride) Extended-Release Capsules. Wyeth Pharmaceuticals Inc., Philadelphia, PA, 2008
   Google Scholar
• Eckert L, Lancon C. Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons. BMC Psychiatry 2006;6:30
   PubMed Web of Science ®Google Scholar
• Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002;180:396-404
   PubMed Web of Science ®Google Scholar
• Thase ME. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-41
   PubMed Web of Science ®Google Scholar
• Wellington K, Perry CM. Venlafaxine extended-release: a review of its use in the management of major depression. CNS Drugs 2001;15:643-69
   PubMed Web of Science ®Google Scholar
• Drugs.com. Top 200 Drugs for 2007 by Sales. http://www.drugs.com/top200.html. Accessed December 12, 2008
   Google Scholar
• Sobocki P, Ekman M, Ovanfors A, et al. The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder. Int J Clin Pract 2008;62:623-32. Epub 2008 Feb 15
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Electronic Orange Book [Query for venlafaxine]. http://www.fda.gov/cder/ob/docs/queryai.htm. Accessed December 12, 2008
   Google Scholar
• US Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations – 28th Edition. http://www.fda.gov/cder/orange/obannual.pdf. Accessed December 12, 2008
   Google Scholar
• Vivian JC. Generic-substitution laws. US Pharm 2008;33:30-4
   Google Scholar
• PriceRx. Wholesale acquisition cost for Effexor XR and venlafaxine extended release tablets. Medispan, February 17, 2009
   Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97
   PubMed Web of Science ®Google Scholar
• Atreja A, Bellam N, Levy SR. Strategies to enhance patient adherence: making it simple. Med Gen Med 2005;7:4
   PubMedGoogle Scholar
• Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther 2003;25:2289-304
   PubMed Web of Science ®Google Scholar
• Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005;165:1147-52
   PubMed Web of Science ®Google Scholar
• Frishman WH. Importance of medication adherence in cardiovascular disease and the value of once-daily treatment regimens. Cardiol Rev 2007;15:257-63
   PubMedGoogle Scholar
• Puigventós F, Riera M, Delibes C et al. [Adherence to antiretroviral drug therapy. A systematic review]. Med Clin (Barc) 2002;119:130-7
   PubMed Web of Science ®Google Scholar
• Halkitis P, Palamar J, Mukherjee P. Analysis of HIV medication adherence in relation to person and treatment characteristics using hierarchical linear modeling. AIDS Patient Care STDS 2008;22:323-35
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Ripamonti D, Arici C, et al. Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV Clin Trials 2002;3:371-8
   PubMedGoogle Scholar
• Stone VE. Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. Clin Infect Dis 2001;33:865-72
   PubMed Web of Science ®Google Scholar
• Demyttenaere K, Haddad P. Compliance with antidepressant therapy and antidepressant discontinuation symptoms. Acta Psychiatr Scand 2000;101:50-6
   Web of Science ®Google Scholar
• Lin EH, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care 1995;33:67-74
   PubMed Web of Science ®Google Scholar
• Hylan TR, Dunn RL, Tepner RG, et al. Gaps in antidepressant prescribing in primary care in the United Kingdom. Int Clin Psychopharmacol 1998;13:235-43
   PubMed Web of Science ®Google Scholar
• Demyttenaere K, Adelin A, Patrick M, et al. Six-month compliance with antidepressant medication in the treatment of major depressive disorder. Int Clin Psychopharmacol 2008;23:36-42
   PubMed Web of Science ®Google Scholar
• Burton WN, Chen CY, Conti DJ, et al. The association of antidepressant medication adherence with employee disability absences. Am J Manag Care 2007;13:105-12
   PubMed Web of Science ®Google Scholar
• Stein MB, Cantrell CR, Sokol MC, et al. Antidepressant adherence and medical resource use among managed care patients with anxiety disorders. Psychiatr Serv 2006;57:673-80
   PubMed Web of Science ®Google Scholar
• Madden JM, Graves AJ, Zhang F, et al. Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D. JAMA 2008;299:1922-8
   PubMed Web of Science ®Google Scholar
• Briesacher BA, Gurwitz JH, Soumerai SB. Patients at-risk for cost-related medication nonadherence: a review of the literature. J Gen Intern Med 2007;22:864-71
   PubMed Web of Science ®Google Scholar
• Bambauer KZ, Safran DG, Ross-Degnan D, et al. Depression and cost-related medication nonadherence in Medicare beneficiaries. Arch Gen Psychiatry 2007;64:602-8
   PubMed Web of Science ®Google Scholar
• Bosworth HB, Voils CI, Potter GG, et al. The effects of antidepressant medication adherence as well as psychosocial and clinical factors on depression outcome among older adults. Int J Geriatr Psychiatry 2008;23:129-34
   PubMed Web of Science ®Google Scholar
• Akerblad AC, Bengtsson F, von Knorring L, Ekselius L. Response, remission and relapse in relation to adherence in primary care treatment of depression: a 2-year outcome study. Int Clin Psychopharmacol 2006;21:117-24
   PubMed Web of Science ®Google Scholar
• Herrmann S, McKinnon E, John M, et al. Evidence-based, multifactorial approach to addressing non-adherence to antiretroviral therapy and improving standards of care. Intern Med J 2008;38:8-15
   PubMed Web of Science ®Google Scholar
• Hommel KA, Davis CM, Baldassano RN. Medication adherence and quality of life in pediatric inflammatory bowel disease. J Pediatr Psychol 2008;33:867-74
   PubMed Web of Science ®Google Scholar
• Tindall WN, Boltri JM, Wilhelm SM. Mild-to-moderate ulcerative colitis: your role in patient compliance and health care costs. J Manag Care Pharm 2007;13:2-12
   PubMed Web of Science ®Google Scholar
• Bender B, Zhang L. Negative affect, medication adherence, and asthma control in children. J Allergy Clin Immunol 2008;122:490-5
   PubMed Web of Science ®Google Scholar
• Sun SX, Liu GG, Christensen DB, Fu AZ. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin 2007;23:2305-12
   PubMed Web of Science ®Google Scholar
• Chernew ME, Shah MR, Wegh A, et al. Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff (Millwood) 2008;27:103-12
   PubMed Web of Science ®Google Scholar
• Ye X, Gross CR, Schommer J, et al. Association between copayment and adherence to statin treatment initiated after coronary heart disease hospitalization: a longitudinal, retrospective, cohort study. Clin Ther 2007;29:2748-57
   PubMed Web of Science ®Google Scholar